GT Biopharma (GTBP)
Developer of natural-killer-cell engagers for cancer and autoimmune disease.
Something off on this page? Send us feedback.
Develops TriKE fusion proteins that activate natural killer cells against cancer targets, with a preclinical autoimmune program. The asset-light business has no approved products or revenue and depends on University of Minnesota licenses, external development partners, and additional funding.
Develops TriKE and Dual Targeting TriKE fusion proteins that connect natural killer cells to cancer-cell antigens while supplying an IL-15 signal. The active pipeline includes GTB-3650 for acute myeloid leukemia and high-risk myelodysplastic syndrome, GTB-5550 for advanced solid tumors, and GTB-7550, a preclinical CD19 program for lupus and other autoimmune disorders.
Operates as a virtual, asset-light biopharmaceutical business with worldwide licensed rights from the University of Minnesota and clinical execution centered in the United States. No approved products or product revenue support the business; development relies on the university, consultants, research institutions, contract manufacturers, and external funding.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.0M · Total debt $0 · Total assets $5.8M · Shareholders' equity $3.6M
- Revenue
- $0
- Operating income
- −$4.5M
- Net income
- −$4.5M
No dividends on record.
| Institutions | 4.66% | 84.1K shares | |
|---|---|---|---|
| 58 holders · as of Jun 30, 2026 | |||
| Strategic holders | 9.99% | 180.3K shares | |
| 1 holder · as of Sep 15, 2026 | |||
| Other | 85.35% | 1.54M shares | |
| remainder | |||
1.80M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (1.80M in the company's Sep 23, 2026 report, 1.26M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RainForest Partners, LLCStrategic | 9.99% | 180,258 | filed Sep 15, 2026 |
Vanguard Capital Management LLCInstitution | 0.83% | 376,399 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.59% | 266,788 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.50% | 225,938 | as of Jun 30, 2026 |
HRT Financial LPInstitution | 0.24% | 107,140 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Innate Pharma (ADR)
Closest NK-cell-engager platform across myeloid and B7-H3 programs.
- Pfizer
Approved CD33 therapy sets a direct AML treatment benchmark.
- Merck
Global co-developer of a leading B7-H3 solid-tumor ADC.
- Cabaletta Bio
Clinical CD19 CAR-T program pursues deep B-cell depletion in lupus.
- Kyverna Therapeutics
Later-stage CD19 CAR-T program targets B-cell-driven autoimmunity.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GT Biopharma | $7.10 | 0.00% | $9.1M | — | — | — | — |
| Innate Pharma (ADR) | $1.77 | +0.54% | $169.0M | — | — | 136.6 | +12.9% |
| Pfizer | $28.15 | −0.05% | $159.19B | 36.9 | 10.1 | 2.5 | +2.6% |
| Merck | $148.11 | +0.07% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Cabaletta Bio | $2.23 | +0.68% | $407.6M | — | — | — | — |
| Kyverna Therapeutics | $7.10 | +0.28% | $456.6M | — | — | — | — |
| Median | 78.8 | 13.6 | 5.6 | +5.1% |